<DOC>
	<DOCNO>NCT00324480</DOCNO>
	<brief_summary>This phase I trial study side effect best dose vorinostat give together alvocidib treat patient advance solid tumor . Drugs use chemotherapy , vorinostat alvocidib , work different way stop growth tumor cell , either kill cell stop dividing . Vorinostat may also stop growth tumor cell block enzymes need cell growth . Giving vorinostat together alvocidib may kill tumor cell .</brief_summary>
	<brief_title>Vorinostat Alvocidib Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose vorinostat ( SAHA ) give combination flavopiridol ( alvocidib ) patient advance solid tumor . II . Obtain preliminary data therapeutic activity SAHA flavopiridol patient . III . Evaluate role p21 , p53 , apoptotic marker relative treatment response patient treat regimen . OUTLINE : This multicenter , open label , non-randomized , dose-escalation study vorinostat ( SAHA ) . Before begin course 1 study therapy , patient receive oral SAHA day 1-3 order ensure tolerability drug . Beginning 1 week later , patient receive oral SAHA daily day 1-3 8-10 fixed-dose alvocidib intravenously ( IV ) 1 hour day 2 9 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos SAHA maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . An additional 10 patient treat MTD SAHA combination fixed-dose alvocidib . Once MTD SAHA combination fixed-dose alvocidib determine , patient receive oral SAHA one dose level MTD daily day 1-3 8-10 divided-dose alvocidib IV 30 minute follow alvocidib IV 4 hour day 2 9 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . If schedule well-tolerated , MTD SAHA combination divided-dose flavopiridol determine . An additional 10 patient treat MTD SAHA combination divided-dose alvocidib . Patients undergo blood draw day 1 9 course 1 pharmacokinetic analysis . After completion study treatment , patient follow 4 week .</detailed_description>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<criteria>Histologically confirm solid tumor Metastatic unresectable disease Standard curative palliative measure exist longer effective No hematologic malignancies No known brain metastasis ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 1.5 mg/dL AST ALT ≤ 2.5 time upper limit normal Creatinine normal OR creatinine clearance ≥ 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history allergic reaction attribute compound similar chemical biologic composition study drug No uncontrolled intercurrent illness , include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would preclude study compliance Recovered prior therapy At least 2 week since prior histone acetylase inhibitor , include valproic acid At least 2 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) At least 2 week since prior investigational therapy At least 2 week since prior radiotherapy No concurrent combination antiretroviral therapy HIVpositive patient No concurrent commonly use vitamin , antioxidant , herbal preparation supplement A single tablet multivitamin allow No concurrent anticancer agent therapy mailgnancy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>